GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + Dofetilide
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Long QT Syndrome
Conditions
Long QT Syndrome
Trial Timeline
Feb 1, 2015 → May 1, 2015
NCT ID
NCT02365532About GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + Dofetilide
GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + Dofetilide is a phase 1 stage product being developed by Gilead Sciences for Long QT Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02365532. Target conditions include Long QT Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02365532 | Phase 1 | Completed |
Competing Products
16 competing products in Long QT Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ensitrelvir | Shionogi | Phase 2 | 52 |
| TBM100 | Novartis | Approved | 85 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| Placebo + Ranolazine | Gilead Sciences | Phase 2 | 51 |
| GS-6615 | Gilead Sciences | Phase 1 | 32 |
| Eleclazine + Eleclazine placebo | Gilead Sciences | Phase 3 | 76 |
| Nirmatrelvir + Ritonavir + Placebo | Pfizer | Phase 2 | 51 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| N-803 (IL-15 Superagonist) | ImmunityBio | Phase 2 | 49 |
| Anktiva | ImmunityBio | Phase 2 | 49 |
| UX007 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |